



**FOR IMMEDIATE RELEASE**

## **Affimed CEO to Present at the Jefferies 2015 Global Healthcare Conference – London**

*Heidelberg, Germany, November 11, 2015* – Affimed N.V. (Nasdaq: AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the Jefferies Autumn 2015 Global Healthcare Conference – London, to be held November 18-19, 2015. In addition, Dr. Hoess has been invited to participate in Jefferies’ panel discussion titled “Biotech Financing - Finding the Right Investor Base, US vs. Europe” to outline and discuss Affimed’s listing venue decision as an EU-based company listing on the Nasdaq.

### Panel Discussion

Wednesday, November 18, at 12:20 p.m. (GMT)

### Corporate Overview Presentation

Wednesday, November 18, 1:20-2:00 p.m. (GMT)

To access a simultaneous webcast of Dr. Hoess’ corporate overview presentation online, log on to <http://wsw.com/webcast/jeff92/afmd> or go to the “Events” section on the “Media” page of the Affimed website at <http://www.affimed.com/events.php>.

A replay of the webcast will be available from Affimed’s website for 30 days following the conference. Dr. Hoess’ presentation will be available for download in PDF format immediately following the conference presentation in the “Events” section of the Media page of Affimed’s website at <http://www.affimed.com/events.php>.

### **About Affimed N.V.**

Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells

or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit [www.affimed.com](http://www.affimed.com).

**Contact:**

Affimed N.V.

Caroline Stewart, Head IR & Communication

Phone: +1 347-394-6793

E-Mail: [IR@affimed.com](mailto:IR@affimed.com) or [c.stewart@affimed.com](mailto:c.stewart@affimed.com)

**Media requests:**

Anca Alexandru or Gretchen Schweitzer

MacDougall Biomedical Communications

Phone: +49 89 2424 3494 or

+49 172 861 8540

E-Mail: [gschweitzer@macbiocom.com](mailto:gschweitzer@macbiocom.com)